Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$11.3M
4M shares
52-week range
$1.26 – $46.50
4% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
183.56%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39.9K | $215.0K | $74.6M | $97.9M | $34.2M | $6.8M | $3.9M | $622.5K |
| Cost of revenue | $9.4K | $112.4K | $16.6M | $11.6M | $5.5M | $4.2M | $999.1K | $222.4K |
| Gross profit | $30.5K | $102.5K | $58.0M | $86.3M | $28.7M | $2.6M | $2.9M | $400.1K |
| Gross margin | 76.5% | 47.7% | 77.7% | 88.2% | 84.0% | 38.6% | 74.5% | 64.3% |
| R&D | $1.4M | $1.4M | $3.2M | $15.0M | $17.4M | $23.0M | $21.0M | $19.1M |
| Operating income | −$6.1M | −$5.9M | $41.7M | $46.1M | −$27.0M | −$42.7M | −$40.1M | −$31.3M |
| EBITDA | −$6.1M | −$6.0M | $41.8M | $46.0M | −$10.3M | −$36.9M | −$36.2M | −$47.4M |
| Net income | −$6.3M | −$6.2M | $42.5M | $36.7M | −$14.2M | −$35.3M | −$37.6M | −$46.9M |
| Net margin | -15714.3% | -2882.0% | 57.0% | 37.5% | -41.6% | -518.7% | -961.4% | -7533.6% |
| EPS (diluted) | -15.00 | -11.09 | 1.52 | 36.90 | -13.57 | -36.00 | -37.20 | -35.25 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $552400 | $-12.15 | $-12.15–$-12.15 | 1 |
| 2027 | $17M | $-12.00 | $-12.00–$-12.00 | 1 |
| 2028 | $59M | $-6.90 | $-6.90–$-6.90 | 1 |
| 2029 | $137M | $6.60 | $6.60–$6.60 | 1 |
Forward consensus · source: Financial Modeling Prep
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
www.codiagnostics.comNo one on the platform currently holds CODX.
No tracked institution reports a position in CODX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-01-02 | 1-for-30reverse |
No one on the platform has traded CODX yet.
| $3M |
| — |
| NVNOenVVeno Medical Corporation | $10.84 | -1.90% | $178893 | — |
| PRPHProPhase Labs, Inc. | $0.10 | +0.00% | $473701 | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 0.9× sales vs its 6.9× historical median P/S.
Fair value ≈ $23.90 · price $2.98 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$CODX need some Of that Ebola $$$!!! $MRK $MRNA $AEMD $VRAX
View on StockTwits ↗$CODX A peek inside CODX facility https://www.linkedin.com/posts/bioutah-co-lifescienceselevated-ugcPost-7475186418999439360-2mGn/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAFjXGZcBhXwZH9_iFWZo5edPFCgnaenwTFM&utm_campaign=copy_link
View on StockTwits ↗$CODX soon to be 6 month since trials were supposed to have started 😳
View on StockTwits ↗$CODX new post from CoSara “CoSara 's oligo lab is now also capable of synthesizing: * Unlabelled PCR primers * Labelled PCR Primers and * Special Primers” https://www.linkedin.com/posts/cosara-diagnostics-oligo-lab-ugcPost-7477293861522952194-vpEx/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAFjXGZcBhXwZH9_iFWZo5edPFCgnaenwTFM&utm_campaign=copy_link
View on StockTwits ↗$CODX the 52 weeks low is $1.26. I can wait. There are better plays out there than this Ebola stock. Good luck
View on StockTwits ↗$CODX more funding needed https://share.google/fPBO7zxz8oM34YMk5
View on StockTwits ↗$CODX bottom Short interest dropped sharply recently — down ~65% from the prior period (from ~349K shares). This indicates improving sentiment or reduced bearish b
View on StockTwits ↗$CODX there is no bottom since the pump. I’ve been eyeing on this stock, but no entry price yet. Where is the bottom
View on StockTwits ↗$CODX why buy now Wait for 5$ 😂 x10 https://share.google/PFfHu6sV1544hhsgr
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.